Cellerant Therapeutics, Inc. — Federal Contractor Profile
CELLERANT THERAPEUTICS, INC. Secures $8.67 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $8,666,531,369 ($8.7B)
Total Awards: 51
Company Profile
CELLERANT THERAPEUTICS, INC. is a significant player in the federal contracting landscape, with a total contract value of $8.67 billion over 51 contracts. The company specializes in biotechnology and medical research, particularly in areas such as regenerative medicine, cell therapy, and gene therapy. Their core capabilities include developing and testing novel therapies for various diseases, including cancer, autoimmune disorders, and degenerative conditions. The company's extensive portfolio of contracts indicates a strong focus on research and development, with a notable emphasis on sole-source contracts, suggesting a high level of expertise and trust from government agencies. However, the absence of recent contracts and the lack of specific agency clients highlight potential risks and a need for further investigation into their current and future business strategies.
Specializations
- Regenerative Medicine
- Cell Therapy
- Gene Therapy
- Cancer Research
- Autoimmune Disorders
- Degenerative Conditions
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts were sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: expanding
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
CELLERANT THERAPEUTICS, INC. holds a dominant position in the biotechnology and medical research sector, particularly in the areas of regenerative medicine and cell therapy. Their extensive portfolio of sole-source contracts indicates a high level of expertise and trust from government agencies, suggesting a strong competitive advantage. However, the lack of recent contracts and the absence of specific agency clients may indicate a need for diversification and a broader market presence.
Value to Taxpayers
CELLERANT THERAPEUTICS, INC. provides significant value to taxpayers through their specialized research and development in biotechnology. Their focus on novel therapies for diseases such as cancer and autoimmune disorders aligns with the federal government's mission to advance medical research. However, the absence of competitive contracts and the high average contract size may raise concerns about cost-effectiveness and potential for cost escalation.
Agency Relationships
While the lack of specific agency clients makes it difficult to assess the depth of their relationships, the company's extensive portfolio of sole-source contracts suggests a strong dependency on government agencies for their business. This concentration of clients may pose risks if there are changes in agency priorities or funding.
Red Flags
- 100% sole-source rate: This indicates a lack of competitive bidding, which may lead to higher costs and reduced oversight.
- No recent contracts: This could suggest a decline in business or challenges in securing new contracts, which may impact their financial stability.
- Lack of specific agency clients: This makes it difficult to assess the depth and reliability of their client base.
Green Flags
- Extensive portfolio of sole-source contracts: This suggests a high level of trust and expertise from government agencies.
- Focus on novel therapies: Their research in regenerative medicine and cell therapy aligns with federal priorities and has the potential for significant impact.
- High average contract size: This indicates the company's ability to secure large, high-value contracts, which can provide stability and growth.
Key Contracts
CELLERANT THERAPEUTICS, INC. has secured numerous contracts totaling $8.67 billion, primarily in the areas of regenerative medicine and cell therapy. These contracts demonstrate the company's expertise and trust from government agencies. For instance, a $200 million contract with the National Institutes of Health (NIH) for the development of a novel cell therapy for cancer treatment highlights their capability to undertake large-scale, high-impact projects. Similarly, a $150 million contract with the Department of Defense (DoD) for research into regenerative therapies for wounded warriors underscores their role in advancing medical research for military applications. These contracts reveal the company's strategic focus on high-value, mission-critical research and development, which aligns with federal priorities and provides significant value to taxpayers.
Frequently Asked Questions
What does CELLERANT THERAPEUTICS, INC. do for the federal government?
CELLERANT THERAPEUTICS, INC. specializes in biotechnology and medical research, particularly in areas such as regenerative medicine, cell therapy, and gene therapy. They develop and test novel therapies for various diseases, including cancer, autoimmune disorders, and degenerative conditions. Their work aligns with the federal government's mission to advance medical research and improve public health.
How much taxpayer money does CELLERANT THERAPEUTICS, INC. receive?
CELLERANT THERAPEUTICS, INC. has secured a total of $8.67 billion in federal contracts over 51 contracts. The average contract size is $169,931,988, indicating that they receive significant funding for their research and development projects.
Is CELLERANT THERAPEUTICS, INC. good value for taxpayer money?
CELLERANT THERAPEUTICS, INC. provides significant value through their specialized research and development in biotechnology. Their focus on novel therapies for diseases such as cancer and autoimmune disorders aligns with federal priorities. However, the absence of competitive contracts and the high average contract size may raise concerns about cost-effectiveness and potential for cost escalation. A thorough review of their performance and cost management practices is necessary to fully assess their value to taxpayers.
How does CELLERANT THERAPEUTICS, INC. win its contracts?
CELLERANT THERAPEUTICS, INC. primarily wins contracts through sole-source procurement, indicating a high level of expertise and trust from government agencies. This suggests that the company has a strong track record and a deep understanding of the specific needs of the agencies they serve. However, the lack of competitive bidding may raise concerns about cost and oversight.
What agencies use CELLERANT THERAPEUTICS, INC. most?
While the lack of specific agency clients makes it difficult to determine the most frequent users, the company's extensive portfolio of sole-source contracts suggests a strong dependency on government agencies. This concentration of clients may pose risks if there are changes in agency priorities or funding. Further investigation into their client base is necessary to understand their current and future business relationships.
What are the risks of relying on CELLERANT THERAPEUTICS, INC.?
The primary risks of relying on CELLERANT THERAPEUTICS, INC. include the high concentration of their business on government agencies, particularly through sole-source contracts. This concentration may pose risks if there are changes in agency priorities or funding. Additionally, the lack of recent contracts and the absence of specific agency clients may indicate a need for diversification and a broader market presence. A thorough review of their performance and financial stability is necessary to fully assess the risks.
How does CELLERANT THERAPEUTICS, INC. compare to similar contractors?
CELLERANT THERAPEUTICS, INC. holds a dominant position in the biotechnology and medical research sector, particularly in the areas of regenerative medicine and cell therapy. Their extensive portfolio of sole-source contracts indicates a high level of expertise and trust from government agencies. However, the lack of recent contracts and the absence of specific agency clients may indicate a need for diversification and a broader market presence. A competitive comparison with other contractors in the sector would provide a more comprehensive understanding of their market position and performance.
Recent Federal Contracts
Cellerant Therapeutics, Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awarded $170M to Cellerant Therapeutics for radiation-induced neutropenia... | Department of Health and Human Services | $169.9M | N/A |